Skip to main content
3D Medicines Inc. logo

3D Medicines Inc. — Investor Relations & Filings

Ticker · 1244 ISIN · KYG8872R1011 HKEX Manufacturing
Open in API
Filings indexed 145 across all filing types
Latest filing 2023-04-03 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1244

About 3D Medicines Inc.

https://www.3d-medicines.com

3D Medicines Inc. is an oncology-focused, commercial-stage biopharmaceutical company specializing in the development and commercialization of next-generation immuno-oncology therapies. The company leverages global research and development capabilities and internal discovery platforms to advance a pipeline of innovative drug candidates. Its core mission is to address unmet medical needs in cancer treatment, aiming to transform cancer into a chronic disease and provide substantial value to patients and healthcare providers globally.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return report for equity issuers and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules. It details movements in authorized and issued share capital, confirms compliance with listing rules, and is submitted to the Hong Kong Exchanges and Clearing Limited. The content focuses on share capital movements and confirmations related to securities issuance, not on financial performance, management changes, or earnings. It is a regulatory compliance filing related to share capital movements and confirmations rather than a financial report or announcement of voting results. Given the nature and format, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2023-04-03 English
Terms of Reference for the Remuneration Committee
Remuneration Information Classification · 95% confidence The document is titled 'Terms of Reference for the Remuneration Committee' and details the committee's structure, duties, membership, authority, and reporting procedures. It focuses on the remuneration policies and governance related to directors and senior management compensation. There are no financial statements, earnings data, or regulatory filings of financial results. The content is about governance and compensation policies rather than a report of compensation paid or a proxy statement. This matches the definition of a Remuneration Information report, which details compensation for top executives and directors. The document length is sufficient and contains substantive content on remuneration committee terms, not just an announcement or summary. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2023-03-31 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022
Annual Report Classification · 100% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022' and contains detailed financial highlights, including revenue, cost of sales, gross profit, research and development expenses, and selling and marketing expenses for the full fiscal year 2022. It also includes a management discussion and analysis section, business highlights, pipeline information, and detailed financial data. The document is prepared in accordance with IFRS and audited by Ernst & Young, indicating it is a comprehensive annual financial report. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is not merely an announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K equivalent). FY 2022
2023-03-30 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 95% confidence The document is an announcement from the Board of Directors of 3D Medicines Inc. regarding the scheduling of a board meeting to approve the annual results for the financial year ended December 31, 2022, and to consider the payment of a final dividend. The document does not contain the actual annual results or financial data but merely announces the date of the board meeting where these will be approved and announced. The document length is short (1398 characters) and it is clearly an announcement rather than the report itself. According to the classification rules, such announcements about the timing of report approvals or releases fall under Report Publication Announcement (RPA).
2023-03-16 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities for the month ended 28 February 2023. It details movements in authorized and issued shares, confirms compliance with listing rules, and includes confirmations by a director. The document is regulatory in nature, reporting share capital and share issuance movements, but it is not a full financial report, earnings release, or management discussion. It is a regulatory filing reporting share capital and securities movements under the Exchange Listing Rules Chapter 19B. The document is about share capital and securities movements but does not announce new share issues or capital changes per se, nor is it a proxy, voting result, or director dealing report. It fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document that does not fit other specific categories.
2023-03-01 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return on movements in securities, specifically focusing on changes in authorised and issued share capital for the month ended 31 January 2023. It includes data on share capital, issued shares, details of share movements including partial exercise of over-allotment options, and confirmations by a company director. The document is submitted to the Hong Kong Exchanges and Clearing Limited and follows the format of a regulatory return under the Exchange Listing Rules. It is not a full financial report, earnings release, or management discussion, but rather a regulatory filing reporting share capital movements and confirmations related to securities issuance. Therefore, it fits best under the category of Regulatory Filings (RNS).
2023-02-06 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.